Seres Therapeutics, Inc. (NASDAQ:MCRB) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Tuesday, August 1st.
A number of other brokerages have also commented on MCRB. BidaskClub raised shares of Seres Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 25th. Canaccord Genuity set a $20.00 price objective on shares of Seres Therapeutics and gave the company a “buy” rating in a research report on Monday, June 12th. Cantor Fitzgerald set a $16.00 price objective on shares of Seres Therapeutics and gave the company a “buy” rating in a research report on Thursday, May 4th. Cowen and Company reissued a “buy” rating on shares of Seres Therapeutics in a research note on Friday, May 19th. Finally, Zacks Investment Research cut shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Seres Therapeutics presently has an average rating of “Buy” and an average price target of $17.00.
Seres Therapeutics (MCRB) traded down 2.93% during trading on Tuesday, reaching $12.94. The company had a trading volume of 160,677 shares. Seres Therapeutics has a 12-month low of $8.85 and a 12-month high of $15.09. The firm has a 50-day moving average price of $12.77 and a 200 day moving average price of $10.81. The stock’s market cap is $524.23 million.
Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.69) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.59) by $0.10. The company had revenue of $3 million for the quarter, compared to analyst estimates of $3 million. Seres Therapeutics had a negative net margin of 441.38% and a negative return on equity of 80.21%. The firm’s quarterly revenue was up .0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.70) EPS. Equities research analysts predict that Seres Therapeutics will post ($2.48) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This report was posted by BNB Daily and is the property of of BNB Daily. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.baseball-news-blog.com/2017/08/19/seres-therapeutics-inc-mcrb-upgraded-at-valuengine-updated-updated.html.
Hedge funds have recently bought and sold shares of the stock. Voya Investment Management LLC acquired a new stake in Seres Therapeutics during the second quarter worth $114,000. American International Group Inc. boosted its stake in Seres Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 10,977 shares of the biotechnology company’s stock worth $124,000 after buying an additional 727 shares during the last quarter. Fox Run Management L.L.C. acquired a new stake in Seres Therapeutics during the first quarter worth $136,000. Advisor Group Inc. boosted its stake in Seres Therapeutics by 100.7% in the second quarter. Advisor Group Inc. now owns 14,050 shares of the biotechnology company’s stock worth $160,000 after buying an additional 7,050 shares during the last quarter. Finally, State of Wisconsin Investment Board acquired a new stake in Seres Therapeutics during the second quarter worth $169,000. 75.28% of the stock is currently owned by institutional investors and hedge funds.
About Seres Therapeutics
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.